Biogen's commercial chief hits the road; FDA accepts Allergan's Dalvance sNDA;

@FiercePharma: A U.S. nonprofit says it has a better way to make generic drugs. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Found this today on the futile hunt for things to write about. Five songs about #pharma. More #Friday | Follow @CarlyHFierce

> Biogen commercial chief Tony Kingsley is departing the company. Release

> The FDA has accepted Allergan's application to expand the label of Dalvance to include the treatment of acute bacterial skin and skin structure infections in adults. Release

> UCB is planning to seek European approval for epilepsy med Vimpat as a monotherapy during the first half of next year. Report

> Presidential hopeful Bernie Sanders (D-VT) plans to oppose U.S. President Barack Obama's nominee for FDA Commissioner, Robert Califf. Report

Medical Device News

@FierceMedDev: ICYMI: GE Ventures reaffirms commitment to VC with med tech startup program. Article | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2

@EmilyWFierce: CalTech team creates one-time contraceptive vaccine for feral animals. More from FierceAnimalHealth | Follow @EmilyWFierce

> Procyrion raises $10M to get minimally invasive, mini heart pump in the clinic. More

> Zoll completes rollout of the sole CPR device indicated for sudden cardiac arrest. News

Biotech News

@FierceBiotech: Roche looks to shake up the MS market with some promising Phase III data. Report | Follow @FierceBiotech

@JohnCFierce: Westphal's Verastem slashes staff in the wake of a clinical trial flop. News | Follow @JohnCFierce

> Lilly upgrades its NYC research hub, adding 50 jobs in an immuno-oncology push. Story

> Roche picks up a new autoimmune drug with $580M Adheron deal. Report

And Finally... High cancer drug prices in China are creating a lucrative market in Hong Kong. More